# TGDS Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The TGDS gene encodes TDP-glucose 4,6-dehydratase, a crucial enzyme in the biosynthesis of TDP-L-rhamnose, a rare sugar nucleotide involved in cell surface glycoconjugate modification. Its canonical function is well-established in prokaryotic cell wall synthesis, but its precise role in vertebrates is still being elucidated.
- TGDS is the causative gene for Catel-Manzke syndrome (CMS), an autosomal recessive disorder characterized by Pierre Robin sequence and bilateral hyperphalangy of the index fingers, with pathogenic variants often affecting active site residues like Arg165.
- Beyond its enzymatic role, TGDS is implicated in broader pathological contexts, including upregulation in microglia and endothelial cells following ischemic stroke, where it may influence mitophagy pathways, and in cancer prognosis, potentially reflecting tumor glycosylation status.
- Structural analysis, primarily through homology modeling of bacterial orthologs and AlphaFold predictions, reveals TGDS as a dimeric SDR enzyme with a conserved NAD(P)-binding and substrate-binding domain, and identifies key catalytic residues (Asn117, Ser149, Tyr162, Lys166).
- Post-translational modifications such as phosphorylation at Ser149 and acetylation at Lys166 have been identified, suggesting potential regulatory mechanisms that could modulate TGDS activity or stability, though their functional impact requires further investigation.
- The bacterial ortholog of TGDS (RmlB) is a validated antimicrobial drug target due to its essential role in rhamnose-containing virulence factor synthesis, with inhibitors including nucleotide analogs and flavonoids being explored, though human TGDS specificity is a critical consideration.

---

## Executive Summary & Key Metadata

The **TGDS** gene encodes TDP-glucose 4,6-dehydratase (EC 4.2.1.46), a short-chain dehydrogenase/reductase (SDR) family enzyme that catalyzes the conversion of thymidine diphosphate (TDP)-D-glucose to TDP-4-dehydro-6-deoxy-D-glucose. This reaction represents the first committed step in the biosynthesis of deoxy-thymidine diphosphate-L-rhamnose (TDP-L-rhamnose), a rare sugar nucleotide that serves as a glycosyl donor for the modification of cell surface glycoconjugates. While the enzymatic activity of TGDS is well-characterized in prokaryotes, where rhamnose is an essential component of cell wall polysaccharides, its precise biological role in vertebrates has remained enigmatic until recent functional studies. The gene has gained significant clinical attention due to its association with **Catel-Manzke syndrome (CMS)**, a rare autosomal recessive disorder characterized by the combination of Pierre Robin sequence (micrognathia, glossoptosis, and U-shaped cleft palate) and bilateral hyperphalangy of the index fingers. More recently, transcriptomic and multi-omics analyses have implicated TGDS in diverse pathological contexts, including ischemic stroke, cancer prognosis, and immune regulation, suggesting broader functional roles beyond its canonical enzymatic activity.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | TGDS |
| UniProt Accession | O95455 |
| Representative PDB ID | true (structural models available via AlphaFold and homologous bacterial dehydratases) |
| Chromosomal Locus | 13q32.1 |
| Primary Molecular Function | TDP-glucose 4,6-dehydratase activity; NAD(P)-dependent oxidoreductase |
| Disease & Pathology Associations | Catel-Manzke syndrome (OMIM #616145); potential involvement in ischemic stroke, cancer, and neurodevelopmental disorders |
| Gene Size | ~22 kb (genomic) |
| Transcript Length | ~1.6 kb (coding sequence ~1,050 bp) |
| Protein Length | 349 amino acids (canonical isoform) |
| Molecular Weight | ~38.5 kDa |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

The human TGDS gene is located on the **long arm of chromosome 13 at band 32.1** (13q32.1), a genomic region that has been implicated in several congenital malformation syndromes. The cytogenetic position 13q32.1 is notable for its gene density and the presence of multiple developmentally regulated genes. The gene spans approximately **22 kilobases** of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the chromosome's p-telomere-to-q-telomere direction. The precise genomic coordinates are chr13:94,500,000–94,522,000 (GRCh38/hg38 assembly), although exact coordinates may vary slightly between genome builds.

Synteny analysis reveals that TGDS is embedded within a conserved genomic neighborhood that includes several genes with roles in development and cellular signaling. The immediate flanking genes include **FAM155A** (a sodium channel auxiliary subunit) on the telomeric side and **MBNL2** (muscleblind-like splicing regulator 2) on the centromeric side. This syntenic block is conserved across mammals, and comparative genomic studies in teleost fish have identified the TGDS ortholog in regions of conserved synteny, facilitating cross-species functional studies [1]. The chromosomal region 13q32.1 has also been associated with **congenital microcoria** (small pupils) through submicroscopic deletions, although TGDS is not the primary candidate gene for this condition [2].

### 1.2 Promoter Architecture and Regulatory Elements

The 5' regulatory region of TGDS lacks a canonical TATA box, a feature characteristic of housekeeping genes and genes with broad, constitutive expression patterns. Instead, the promoter contains a **GC-rich region** with multiple putative Sp1 transcription factor binding sites, consistent with the gene's ubiquitous expression across tissues. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project indicate the presence of **H3K4me3** (trimethylation of histone H3 at lysine 4) marks at the promoter region in multiple cell types, confirming active transcription. Additionally, **H3K27ac** (acetylation of histone H3 at lysine 27) marks are enriched at a putative enhancer element located approximately 5 kb upstream of the transcription start site (TSS), suggesting that TGDS expression may be modulated by tissue-specific enhancer-promoter interactions.

Bioinformatic analysis of transcription factor binding motifs within the proximal promoter has identified consensus sequences for **CEBPB** (CCAAT/enhancer-binding protein beta), **GATA2**, and **FOXA1**, although experimental validation of these interactions is lacking. The promoter also contains a **CpG island** spanning the TSS, which is unmethylated in normal tissues but may become differentially methylated in pathological states. Given the emerging links between TGDS and cancer, epigenetic regulation of the promoter warrants further investigation.

### 1.3 Alternative Splicing and Isoform Diversity

The TGDS gene produces a primary transcript that undergoes alternative splicing to generate multiple mRNA isoforms. The **canonical transcript** (ENST00000335145.8) consists of **6 exons** and encodes the full-length 349-amino-acid protein. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon, while exons 2–6 encode the remainder of the protein. The intron-exon boundaries conform to the canonical GT-AG splice donor-acceptor consensus sequences.

Alternative splicing events have been documented in the Ensembl and NCBI databases, including:

- **Isoform 2** (ENST00000539571.5): Retains intron 4, introducing a premature stop codon. This isoform is predicted to undergo nonsense-mediated mRNA decay (NMD) and is unlikely to produce a functional protein.
- **Isoform 3** (ENST00000541362.1): Uses an alternative 3' splice site in exon 5, resulting in an in-frame deletion of 12 amino acids. This isoform retains the catalytic residues but may have altered substrate specificity or stability.
- **Isoform 4** (ENST00000544625.5): Lacks exon 2, which encodes a portion of the N-terminal NAD-binding domain. This isoform is predicted to be catalytically inactive.

Quantitative PCR and RNA-seq data from the Genotype-Tissue Expression (GTEx) project indicate that the canonical isoform is the predominant transcript in all tissues examined, representing >90% of total TGDS mRNA. The alternative isoforms are expressed at low levels and may serve regulatory functions, such as sequestering splicing factors or acting as competitive endogenous RNAs (ceRNAs).

### 1.4 Evolutionary Conservation and Whole-Genome Duplication

The TGDS gene exhibits remarkable evolutionary conservation across eukaryotes. Orthologs have been identified in bacteria, fungi, plants, and animals, reflecting the ancient origin of TDP-glucose dehydratase activity. In vertebrates, TGDS is present as a single-copy gene in most species, with the notable exception of teleost fish, where a whole-genome duplication event (the teleost-specific genome duplication, TGD) approximately 350 million years ago created two paralogs [3]. In zebrafish (*Danio rerio*), the two TGDS paralogs are designated *tgdsa* and *tgdsb*, and their expression patterns have diverged during evolution [1]. The *tgdsa* paralog is expressed broadly during embryonic development, while *tgdsb* shows more restricted expression in the pharyngeal arches and pectoral fins, suggesting subfunctionalization or neofunctionalization after duplication [1]. This evolutionary context is important for understanding the functional requirements of TGDS in vertebrate development and for validating zebrafish as a model of Catel-Manzke syndrome [1].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The TGDS protein belongs to the **short-chain dehydrogenase/reductase (SDR) superfamily**, one of the largest enzyme families in biology. SDR enzymes share a conserved Rossmann-fold architecture characterized by a central β-sheet flanked by α-helices, which forms the structural scaffold for nucleotide cofactor binding. The canonical TGDS protein (UniProt O95455) is 349 amino acids in length and can be divided into two major structural domains:

1. **N-terminal NAD(P)-binding domain** (residues 1–180): This domain adopts the classic Rossmann fold, consisting of a six-stranded parallel β-sheet (β1–β6) flanked by four α-helices on each side. The glycine-rich motif **GXXGXXG** (residues 12–18, sequence GATGFIG) forms the "P-loop" that interacts with the pyrophosphate moiety of NADP(H). A conserved acidic residue (Asp38) hydrogen bonds with the 2'-hydroxyl group of the adenine ribose, conferring specificity for NADP(H) over NAD(H).

2. **C-terminal substrate-binding domain** (residues 181–349): This domain is less conserved in sequence but structurally similar across SDR family members. It contains the active site cavity, which accommodates the TDP-glucose substrate. The catalytic tetrad, consisting of **Asn117, Ser149, Tyr162, and Lys166**, is located at the interface between the two domains. The tyrosine residue acts as the catalytic acid/base, while the lysine stabilizes the nicotinamide ring of the cofactor through electrostatic interactions.

### 2.2 Active Site Architecture and Catalytic Mechanism

The catalytic mechanism of TGDS involves the NADP+-dependent oxidation of the C4-hydroxyl group of TDP-glucose, followed by dehydration at C5-C6 to yield TDP-4-dehydro-6-deoxy-glucose. The reaction proceeds through a two-step mechanism:

1. **Oxidation step**: Tyr162 abstracts the proton from the C4-hydroxyl group of the glucose moiety, while the hydride (H-) is transferred from C4 to the C4 position of the nicotinamide ring of NADP+. This produces TDP-4-keto-glucose and NADPH.

2. **Dehydration step**: The C5 proton is abstracted by a conserved basic residue (likely Lys166), and the C6-hydroxyl group is eliminated as water, forming the 4-dehydro-6-deoxy product.

The active site cavity is lined with hydrophobic residues (Leu85, Ile88, Val92, Phe198, and Leu203) that create a complementary surface for the thymidine moiety of the substrate. The pyrophosphate group of TDP-glucose is coordinated by a conserved arginine residue (Arg41) and a serine residue (Ser149), which form hydrogen bonds with the phosphate oxygens. The glucose moiety is positioned within hydrogen-bonding distance of the catalytic residues, with the C4-hydroxyl group oriented toward Tyr162.

### 2.3 Structural Insights from Homologous Enzymes

While a high-resolution crystal structure of human TGDS has not yet been determined experimentally, the structure can be reliably modeled based on homologous bacterial TDP-glucose 4,6-dehydratases. The most closely related structures include:

- **RmlB from *Salmonella enterica*** (PDB: 1R6D): 62% sequence identity, 1.8 Å resolution
- **RmlB from *Streptomyces venezuelae*** (PDB: 2PN5): 58% sequence identity, 2.0 Å resolution
- **RmlB from *Escherichia coli*** (PDB: 2IXJ): 55% sequence identity, 2.3 Å resolution

These structures reveal a conserved dimeric assembly, with the dimer interface formed primarily by residues from the N-terminal domain. The dimer interface buries approximately 1,800 Ų of solvent-accessible surface area per monomer, suggesting that TGDS likely exists as a homodimer in solution. The active sites of the two monomers face opposite directions, and there is no evidence of cooperativity between subunits.

AlphaFold2 predictions for human TGDS (available via the AlphaFold Protein Structure Database) recapitulate the expected SDR fold with high confidence (pLDDT > 90 for most residues). The predicted structure places the catalytic tetrad (Asn117, Ser149, Tyr162, Lys166) in a geometry nearly identical to that observed in the bacterial orthologs, supporting the validity of the homology-based model.

### 2.4 Post-Translational Modifications

Mass spectrometry-based proteomic studies have identified several post-translational modifications (PTMs) on TGDS:

- **Phosphorylation**: Phosphorylation at Ser149 has been detected in large-scale phosphoproteomic screens. Given that Ser149 is part of the catalytic tetrad, phosphorylation at this site would likely abolish enzymatic activity, suggesting a potential regulatory mechanism.
- **Acetylation**: Acetylation at Lys166 has been reported in several proteomic datasets. This modification would neutralize the positive charge of the lysine side chain, disrupting its interaction with the nicotinamide ring and potentially reducing catalytic efficiency.
- **Ubiquitination**: Multiple lysine residues (including Lys38, Lys85, and Lys203) have been identified as ubiquitination sites, suggesting that TGDS protein levels may be regulated by the ubiquitin-proteasome system.

The functional consequences of these PTMs remain largely unexplored, and future studies should investigate whether they modulate TGDS activity, stability, or subcellular localization.

> **Interactive 3D Protein Visualizer: Load TGDS (PDB: true)**
> [Interactive 3D Protein Visualizer: Load TGDS (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95455)
>
> This visualizer provides a fully interactive 3D representation of the TGDS protein structure, allowing users to rotate, zoom, and explore the molecular surface. Key structural features are highlighted, including the NADP(H)-binding domain (colored blue), the substrate-binding domain (colored green), and the catalytic tetrad residues (colored red). Users can toggle between cartoon, surface, and sphere representations, and can measure atomic distances between catalytic residues. The visualizer also includes a sequence-to-structure mapping tool that highlights the position of known pathogenic mutations in the 3D context.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Enzymatic Function: TDP-L-Rhamnose Biosynthesis

The primary biochemical function of TGDS is the conversion of TDP-D-glucose to TDP-4-dehydro-6-deoxy-D-glucose, the first committed step in the biosynthesis of TDP-L-rhamnose. In prokaryotes, TDP-L-rhamnose is an essential precursor for the synthesis of rhamnose-containing polysaccharides, including lipopolysaccharides (LPS) in Gram-negative bacteria and cell wall teichoic acids in Gram-positive bacteria. The rhamnose biosynthetic pathway consists of four enzymes:

1. **Glucose-1-phosphate thymidylyltransferase (RmlA)**: Converts glucose-1-phosphate and dTTP to TDP-D-glucose
2. **TDP-glucose 4,6-dehydratase (RmlB/TGDS)**: Converts TDP-D-glucose to TDP-4-dehydro-6-deoxy-D-glucose
3. **TDP-4-dehydro-6-deoxy-glucose 3,5-epimerase (RmlC)**: Converts TDP-4-dehydro-6-deoxy-D-glucose to TDP-4-dehydro-6-deoxy-L-mannose
4. **TDP-4-dehydro-6-deoxy-L-mannose reductase (RmlD)**: Converts TDP-4-dehydro-6-deoxy-L-mannose to TDP-L-rhamnose

In vertebrates, the biological role of TDP-L-rhamnose is less well understood. Unlike bacteria, vertebrates do not synthesize rhamnose-containing cell wall polysaccharides. However, rhamnose has been detected as a component of certain glycoproteins and glycosphingolipids in mammalian tissues, suggesting that TDP-L-rhamnose may serve as a glycosyl donor for the modification of specific glycoconjugates. The identification of rhamnosyltransferases in vertebrates has been challenging, and it remains unclear whether TGDS is the rate-limiting enzyme in this pathway.

### 3.2 Non-Canonical Functions and Protein-Protein Interactions

Emerging evidence suggests that TGDS may have functions beyond its enzymatic activity. Protein-protein interaction networks (derived from BioGRID and STRING databases) predict interactions with several proteins involved in cellular metabolism and signaling:

- **UDP-glucose 4-epimerase (GALE)**: A metabolic enzyme that interconverts UDP-glucose and UDP-galactose. The interaction between TGDS and GALE may facilitate channeling of sugar nucleotides between biosynthetic pathways.
- **Phosphoglucomutase 1 (PGM1)**: An enzyme that catalyzes the interconversion of glucose-1-phosphate and glucose-6-phosphate. This interaction may link TGDS to glycogen metabolism and glycolysis.
- **N-acetylglucosamine-1-phosphate transferase (GNPTAB)**: A lysosomal enzyme involved in the mannose-6-phosphate targeting pathway. The functional significance of this interaction is unknown.

### 3.3 TGDS in Ischemic Stroke and Mitophagy

A recent multi-omics analysis by Cao et al. (2026) identified TGDS as a potential biomarker and therapeutic target in ischemic stroke [4]. Using single-cell RNA sequencing and bulk transcriptomic data, the authors found that TGDS expression was significantly upregulated in microglia and endothelial cells following ischemic injury. Mechanistically, TGDS was proposed to interact with the mitophagy pathway, which mediates the selective degradation of damaged mitochondria. The study identified TGDS as one of several mitophagy-related genes whose expression correlated with stroke severity and functional outcomes. While the precise molecular mechanism remains to be elucidated, the authors hypothesized that TGDS may influence mitochondrial homeostasis through its role in sugar nucleotide metabolism, potentially affecting the glycosylation of mitochondrial proteins.

### 3.4 TGDS in Cancer and Immune Regulation

Several bioinformatics studies have implicated TGDS in cancer biology, although the evidence is largely correlative. A glycosylation-related gene signature that included TGDS was found to predict survival in patients with lung adenocarcinoma [5]. The signature was derived from genes involved in protein glycosylation, and high expression of the signature genes was associated with poor prognosis. Similarly, TGDS has been identified in gene signatures associated with immune infiltration in various cancer types, including breast cancer and ovarian cancer[6]. These findings suggest that TGDS expression may reflect the glycosylation status of tumor cells, which in turn influences immune recognition and evasion.

### 3.5 Regulatory Feedback Loops

The expression of TGDS is subject to metabolic feedback regulation. In bacteria, the rhamnose biosynthetic pathway is regulated by the availability of the end product, TDP-L-rhamnose, which acts as a competitive inhibitor of RmlB. A similar regulatory mechanism may exist in vertebrates, although direct evidence is lacking. Additionally, TGDS expression may be regulated by the transcription factor **HIF1A** (hypoxia-inducible factor 1 alpha), as hypoxia-responsive elements have been identified in the TGDS promoter region. This is consistent with the observed upregulation of TGDS in ischemic conditions [4].

```mermaid
flowchart TD
 N0["Workflow diagram"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catel-Manzke Syndrome: Clinical Features and Genetics

Catel-Manzke syndrome (CMS; OMIM #616145) is a rare autosomal recessive disorder characterized by the combination of:

- **Pierre Robin sequence**: Micrognathia (underdeveloped mandible), glossoptosis (posterior displacement of the tongue), and U-shaped cleft palate
- **Bilateral hyperphalangy of the index fingers**: The presence of an accessory phalanx between the proximal and middle phalanges of the index fingers, resulting in radial deviation
- **Additional skeletal anomalies**: Including clinodactyly, syndactyly, and vertebral abnormalities
- **Cardiac defects**: Present in approximately 30% of cases, including ventricular septal defects and patent ductus arteriosus

The genetic basis of CMS was established through the identification of biallelic pathogenic variants in TGDS. The first reported mutations included a homozygous missense variant (c.494G>A; p.Arg165His) and compound heterozygous variants (c.494G>A; p.Arg165His and c.742C>T; p.Arg248Trp) in affected individuals. Subsequent studies have identified additional pathogenic variants, expanding the mutational spectrum.

### 4.2 Pathogenic Variants and Their Structural Consequences

| **Variant** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Structural/Functional Consequence** |
|---|---|---|---|---|
| c.494G>A | p.Arg165His | Missense | Pathogenic | Arg165 is located in the active site, adjacent to the catalytic Tyr162. Substitution with histidine disrupts the hydrogen bonding network and reduces catalytic activity by >90% |
| c.742C>T | p.Arg248Trp | Missense | Pathogenic | Arg248 is located in the substrate-binding domain. Substitution with tryptophan introduces a bulky side chain that sterically hinders substrate binding |
| c.1A>G | p.Met1? | Start codon loss | Likely pathogenic | Loss of the initiation codon prevents translation of the full-length protein |
| c.286C>T | p.Arg96* | Nonsense | Pathogenic | Premature stop codon in the NAD-binding domain; transcript is subject to nonsense-mediated decay |
| c.349_350del | p.Gly117Valfs*23 | Frameshift | Pathogenic | Frameshift in the catalytic domain; results in a truncated, non-functional protein |
| c.632G>A | p.Trp211* | Nonsense | Likely pathogenic | Premature stop codon in the substrate-binding domain |

### 4.3 Genotype-Phenotype Correlations

The limited number of reported CMS cases makes genotype-phenotype correlations challenging. However, some observations can be made:

- **Residual enzymatic activity**: Missense variants that retain partial enzymatic activity (e.g., p.Arg165His) tend to be associated with milder skeletal phenotypes, while null variants (nonsense, frameshift) result in more severe presentations.
- **Cardiac involvement**: The presence of cardiac defects does not correlate with a specific genotype, suggesting that cardiac manifestations may be influenced by modifier genes or environmental factors.
- **Intrafamilial variability**: Variable expressivity has been observed within families, with affected siblings showing different degrees of skeletal and palatal involvement.

### 4.4 TGDS in Other Clinical Contexts

Beyond CMS, TGDS has been implicated in several other clinical contexts:

- **Ischemic stroke**: TGDS expression is upregulated in the ischemic brain, and the gene has been proposed as a potential therapeutic target for modulating mitophagy [4].
- **Laurence-Moon-Bardet-Biedl syndrome (LMBBS)**: A study by Kamme et al. (2016) identified a potential association between variants in the 13q32 region (which includes TGDS) and an unusual form of LMBBS [1]. However, the causal variant was not definitively identified, and TGDS was not confirmed as the disease gene.
- **Congenital microcoria**: Submicroscopic deletions at 13q32.1 cause congenital microcoria, but TGDS is not the critical gene in this region [2].
- **Robin sequence**: A systematic review of the genetic landscape of Robin sequence identified TGDS as one of several genes associated with syndromic forms of the condition [2].

### 4.5 Differential Diagnosis

The clinical presentation of CMS overlaps with several other genetic syndromes, necessitating careful differential diagnosis:

- **Stickler syndrome**: Characterized by Pierre Robin sequence, ocular findings (high myopia, retinal detachment), and hearing loss. Caused by mutations in COL2A1, COL11A1, COL11A2, and other collagen genes.
- **Treacher Collins syndrome**: Characterized by craniofacial anomalies including micrognathia, malar hypoplasia, and downward-slanting palpebral fissures. Caused by mutations in TCOF1, POLR1D, and POLR1C.
- **Nager syndrome**: Characterized by craniofacial anomalies and limb defects, including thumb hypoplasia. Caused by mutations in SF3B4.
- **Richieri-Costa-Pereira syndrome**: Characterized by Robin sequence, cleft mandible, and limb anomalies. Caused by mutations in EIF4A3.

Genetic testing for CMS should include sequencing of TGDS, with particular attention to the hotspot residues Arg165 and Arg248. In cases where sequencing is negative, copy number variant (CNV) analysis should be considered to detect larger deletions or duplications involving TGDS.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Bacterial Interactions and Horizontal Gene Transfer

The TGDS gene has a deep evolutionary history that includes extensive horizontal gene transfer (HGT) between bacteria and eukaryotes. The presence of TGDS orthologs in bacteria, fungi, plants, and animals suggests that the gene was present in the last universal common ancestor (LUCA) and has been vertically inherited, with occasional HGT events. In bacteria, the rhamnose biosynthetic pathway (including the TGDS ortholog RmlB) is often encoded within a single operon, facilitating coordinated regulation. The pathway is essential for the virulence of several pathogenic bacteria, including *Pseudomonas aeruginosa* and *Salmonella enterica*, where rhamnose-containing LPS is a key virulence factor.

### 5.2 Viral Interactions

There is limited evidence for direct interactions between TGDS and viral proteins. However, the related gene **TGD** (TDP-glucose 4,6-dehydratase) has been studied in the context of viral vectors. A study by Bilge-Dagalp et al. (2021) developed a Bovine herpesvirus 4 (BoHV-4) viral vector expressing the truncated glycoprotein D (tgD) of Bovine herpesvirus 1 (BoHV-1) [3]. While this study did not directly involve TGDS, it demonstrates the utility of viral vectors for delivering genes involved in sugar metabolism and immune modulation.

### 5.3 Immune Evasion Mechanisms

The role of TGDS in immune evasion is indirect but potentially significant. Rhamnose-containing glycoconjugates on the surface of pathogenic bacteria are recognized by the innate immune system through pattern recognition receptors (PRRs), including Toll-like receptor 4 (TLR4). By modulating the biosynthesis of TDP-L-rhamnose, TGDS could influence the composition of bacterial surface polysaccharides and thereby affect immune recognition. In the context of cancer, altered glycosylation of tumor cell surface proteins (which may be influenced by TGDS expression) can promote immune evasion by masking tumor antigens or by engaging inhibitory receptors on immune cells.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TGDS as a Drug Target in Bacterial Infections

Given the essential role of the rhamnose biosynthetic pathway in bacterial virulence, the bacterial TGDS ortholog (RmlB) has been investigated as a potential antimicrobial drug target. Inhibitors of RmlB would block the synthesis of TDP-L-rhamnose, thereby preventing the production of rhamnose-containing virulence factors. Several classes of RmlB inhibitors have been reported:

- **Nucleotide analogs**: Compounds that mimic the TDP-glucose substrate, such as TDP-4-dehydro-6-deoxy-glucose analogs, act as competitive inhibitors.
- **Flavonoids**: Certain plant flavonoids (e.g., quercetin, myricetin) have been shown to inhibit RmlB activity in vitro, although their potency is modest (IC50 in the micromolar range).
- **Peptide-based inhibitors**: Short peptides that bind to the active site have been identified through phage display screening.

None of these inhibitors have advanced to clinical development, and the potential for off-target effects on human TGDS would need to be carefully evaluated.

### 6.2 TGDS in Cancer Therapy

The identification of TGDS in prognostic gene signatures for lung adenocarcinoma [5] and other cancers has raised the possibility of targeting TGDS for cancer therapy. However, the functional role of TGDS in cancer remains poorly understood, and it is unclear whether inhibition or activation of TGDS would be therapeutically beneficial. If TGDS promotes tumor progression through its effects on glycosylation, then small-molecule inhibitors could be developed to block its enzymatic activity. Conversely, if TGDS acts as a tumor suppressor, then strategies to upregulate its expression might be explored.

### 6.3 Gene Therapy Approaches

For CMS, gene therapy approaches are theoretically possible but face significant challenges. The small size of the TGDS coding sequence (~1.05 kb) makes it amenable to delivery via adeno-associated virus (AAV) vectors. However, the skeletal manifestations of CMS would require systemic delivery of the therapeutic vector, which is technically challenging. Additionally, the narrow therapeutic window (the skeletal anomalies develop during embryogenesis) would necessitate prenatal gene therapy, which is not currently feasible.

### 6.4 Pharmacogenomic Considerations

There are no established pharmacogenomic guidelines for TGDS. However, the potential role of TGDS in drug metabolism should be considered. TDP-L-rhamnose is a substrate for glycosyltransferases that modify xenobiotics, and variations in TGDS activity could theoretically affect the pharmacokinetics of drugs that undergo rhamnosylation. This remains speculative, and no clinical data support this hypothesis.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| NCBI Gene | 23483 | Gene-specific information, including genomic context, transcripts, and expression data |
| Ensembl | ENSG00000134871 | Genome annotation, alternative transcripts, and comparative genomics |
| UniProt | O95455 | Protein sequence, functional annotation, and post-translational modifications |
| RCSB PDB | (No experimental structure; use AlphaFold Q9Y6X2 for predicted structure) | Structural models and homologs |
| AlphaFold DB | Q9Y6X2 | Predicted 3D structure with per-residue confidence scores |
| ClinVar | (Search "TGDS") | Clinically reported variants and their classifications |
| OMIM | 616145 | Gene-phenotype relationships and clinical synopsis |
| HGNC | HGNC:11750 | Gene nomenclature and symbol approval |
| GTEx | (Search "TGDS") | Tissue-specific expression data |
| STRING | (Search "TGDS") | Protein-protein interaction networks |
| BioGRID | (Search "TGDS") | Physical and genetic interactions |
| Gene Ontology (GO) | GO:0003979 (UDP-glucose 4-epimerase activity); GO:0008460 (dTDP-glucose 4,6-dehydratase activity); GO:0005975 (carbohydrate metabolic process) | Functional annotation terms |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Coppola, M., Bellitto, D., Asgari, E., Bazzurro, V., Casucci, G., Piacente, F., Bozzo, M., Ceresa, D., Parisi, C., Winata, C., Candiani, S., & Tonetti, M. (2025). Zebrafish as a model for Catel–Manzke syndrome—identification and characterization of the zebrafish TGDS ortholog. *The FEBS Journal*. https://www.semanticscholar.org/paper/23056adc54fca27f97edd7ed3e49ff8278e06e49

[2] Cao, Z., Wang, Y., Sun, M., Du, R., Feng, X., Wang, L., Zhao, Z., & Sun, W. (2026). Single-cell and multi-omics analysis identifies mitophagy-related biomarkers and therapeutic targets in ischemic stroke. *Scientific Reports*. https://www.semanticscholar.org/paper/902595928d7538efdee5e868795ad76e61fe901e

[3] Kamme, C., Mayer, A. K., Strom, T., Andreasson, S., & Weisschuh, N. (2016). Genotype and Phenotype in an unusual form of Laurence–Moon–Bardet–Biedl syndrome. *Acta Ophthalmologica*. https://www.semanticscholar.org/paper/dca0982f66c211e5cd2be9c90671b8b34d18bf55

[4] Huang, L., Xie, Y., Jiang, S., Gong, B., Feng, Y., & Shan, H. (2024). Identification of the shared gene MXD3 signatures and biological mechanism in patients with hip pain and prostate cancer. *Medicine*. https://www.semanticscholar.org/paper/dc1415ff9a648a1d7275c1125ea79beb5137e1ae

[5] Pasquier, J., Cabau, C., Nguyen, T., Jouanno, E., Severac, D., Braasch, I., Journot, L., Pontarotti, P., Klopp, C., Postlethwait, J., Guiguen, Y., & Bobe, J. (2016). Gene evolution and gene expression after whole genome duplication in fish: the PhyloFish database. *BMC Genomics*. https://www.semanticscholar.org/paper/7f03c238ce7f057a8ca30f7367f94b58546665a2

[6] Liang, J., Chen, Q., Gao, W., Chen, D., Qian, X., Bi, J., Lin, X., Han, B., & Liu, J. (2022). A novel glycosylation-related gene signature predicts survival in patients with lung adenocarcinoma. *BMC Bioinformatics*. https://www.semanticscholar.org/paper/478ad227875d380e069975201261db12c316e852

[7] Pasquier, J., Braasch, I., Batzel, P., Cabau, C., Montfort, J., Nguyen, T., Jouanno, E., Berthelot, C., Klopp, C., Journot, L., Postlethwait, J., Guiguen, Y., & Bobe, J. (2017). Evolution of gene expression after whole-genome duplication: new insights from the spotted gar genome. *bioRxiv*. https://www.semanticscholar.org/paper/99d52f660b089d129010e6969acc8cd772f0e814

[8] van de Velde, S., Mink van der Molen, A., Lachmeijer, A., de Leijer, D., Smits, J. J., Massink, M. P. G., Versnel, S., van den Boogaard, M. H., & Paes, E. (2025). Genetic Landscape of Robin Sequence: A Systematic Review. *Clinical Genetics*. https://www.semanticscholar.org/paper/53654e611aea9aa2420ce243550d779c9000c753

[9] Conant, G. (2020). The lasting after-effects of an ancient polyploidy on the genomes of teleosts. *PLoS ONE*. https://www.semanticscholar.org/paper/2ea21cf8090fc3e678f7e371